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In 2007, the American Heart Association published a guideline statement dramatically changing its previous
position on the use of antibiotic prophylaxis in patients at risk of infective endocarditis (IE). This year, these
views were incorporated in an update of the 2006 American College of Cardiology/American Heart Association
Guidelines for the Management of Patients With Valvular Heart Disease. The new recommendations represent a
dramatic shift with regard to which patients should receive antibiotic prophylaxis for prevention of IE and for
what procedures. The shift in recommendations is striking in that the recommendations are based not on new
data, but on no data. (There are no large, prospective, randomized double-blind trials testing the efficacy of IE
prophylaxis.) However, available data suggest that there may be no real risk associated with IE prophylaxis. Even
if few cases of IE are successfully prevented using antibiotic prophylaxis, those few cases may represent a favor-
able risk-benefit ratio. On an individual basis, patients with organic heart valve disease who are trying to delay or
avoid surgical intervention have something very real to risk if they develop IE, and a very real benefit if they
avoid it. Pending data from prospective randomized trials, a strategy of individual decision-making by informed
patients may be best. (J Am Coll Cardiol 2009;53:1852–4) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.023a
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bn 2007, the American Heart Association (AHA) published
guideline statement (1) dramatically changing its previous
osition on the use of antibiotic prophylaxis in patients at
isk of infective endocarditis (IE). This year, these views
ere incorporated in an update (2) of the 2006 American
ollege of Cardiology (ACC)/AHA Guidelines for the
anagement of Patients With Valvular Heart Disease (3).
s these 2 revisions have pointed out, the new recommen-
ations represent a dramatic shift with regard to which
atients should receive antibiotic prophylaxis for prevention
f IE and for what procedures. The AHA statement and
ubsequent ACC/AHA guideline update were not pub-
ished in isolation; multiple other cardiac and noncardiac
rganizations have in the past several years published
ecommendations (4–9) that dramatically limit the scope of
atients for whom antibiotic prophylaxis is recommended,
s well as the types of procedures for which designated
atients should receive prophylaxis. What is striking about
hese new recommendations is that the dramatic shift is
ased not on new data, but on no data.
istorical perspective. Since 1955, the AHA has recom-
ended antibiotic prophylaxis for the prevention of IE
rom the Department of Internal Medicine, Division of Cardiovascular Medicine,m
niversity of Michigan, Ann Arbor, Michigan.
Manuscript received August 13, 2008; accepted September 10, 2008.mong patients at increased risk of disease (10). In 1972,
xisting recommendations for prophylaxis during oral pro-
edures were expanded (11) to include gastrointestinal (GI)
ract and genitourinary (GU) tract procedures. Subsequent
ecommendations published in 1977 (12), 1984 (13), 1990
14), and 1997 (15) included more specific content regard-
ng patient risk and procedures that should be covered.
otably, the original recommendations and all subsequent
evisions were based not on data from randomized trials but
n consensus opinion weighing risks and benefit. In pub-
ishing past guidelines, note was made that guidelines for
rophylaxis against IE could pose a medical-legal risk (14) and
hat many cases of IE can be attributed to randomly occurring
acteremia rather than to an invasive procedure (15).
urrent recommendations. The current guidelines (1,2)
hift the recommendation for antibiotic prophylaxis from all
atients with an increased lifetime risk of developing IE to
nly patients with an underlying cardiac condition that
ncreases the risk of an adverse outcome from IE (and
herefore would derive the greatest benefit from preventing
E). Antibiotic prophylaxis for dental procedures is now
ecommended only in patients with a prosthetic heart valve;
revious IE; cyanotic congenital heart disease that is unre-
aired, within 6 months of a repair procedure, or repaired
ut with residual defect at or near the location of prosthetic
aterial; or in cardiac transplant recipients with cardiac
v
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May 19, 2009:1852–4 IE Prophylaxisalvulopathy. Antibiotic prophylaxis is not recommended in
onjunction with GI tract or GU tract procedures.
Citing a rationale for the change in recommendations, the
urrent guidelines (1,2) note the absence of data supporting
he efficacy of antibiotic prophylaxis in the prevention of IE.
limited potential benefit of prophylaxis is cited in that IE
s felt most likely to result from frequent exposure to
andom bacteremia associated with daily activities than
rom bacteremia caused by a dental, GI tract, or GU tract
rocedure, suggesting that prophylaxis may prevent only a
mall number of cases of IE. A potential risk of antibiotic
rophylaxis is cited in the AHA document (1) as a risk of
naphylaxis and in the ACC/AHA guideline update (2) as
more general risk of antibiotic-associated adverse effects.
f note, however, the AHA guideline statement (1) dis-
loses that during the 50 years that the AHA had recom-
ended penicillin as the preferred prophylaxis to prevent
E, no case of fatal anaphylaxis was reported for a patient
eceiving penicillin administered for IE prophylaxis.
The AHA statement (1) explicitly notes that potential
onsequences of the revised recommendations include re-
uced malpractice claims related to IE prophylaxis and
timulation of prospective research on IE prophylaxis. The
atter outcome is echoed in the ACC/AHA guideline
pdate (2), noting that fewer patients receiving IE prophy-
axis will stimulate prospective studies on IE prevention.
bsence of evidence-based medicine. Practitioners in
ardiology have become accustomed to medical decisions
ased largely on evidence-based medicine. In diseases such
s coronary artery disease and heart failure, the presence of
arge numbers of patients with a potentially life-threatening
edical condition, and medical interventions that lend
hemselves to randomization, allow the performance of
rospective randomized clinical trials using “hard” end
oints such as mortality, with results that may dramatically
ffect future patient management. In the past few decades, a
ariety of large, prospective, randomized clinical trials with
creative array of acronyms have redefined (among other
hings) intervention for acute coronary syndromes, medical
herapy for coronary artery disease and heart failure, and
edical and device therapy for a variety of lethal and
onlethal cardiac arrhythmias.
What should we do in the absence of evidence-based
edicine? Some aspects of cardiology do not readily lend
hemselves to randomized controlled trials owing to limited
atient numbers, therapies that are not easy to randomize
e.g., mitral valve repair), or outcomes that are meaningfully
easured only years and even decades after intervention.
hese limitations affect most decisions for patients with
eart valve disease, and the published guidelines for the
anagement of such patients rely heavily on results of small
onrandomized trials and on expert opinion. Notably, most
ecommendations in the 2006 ACC/AHA guidelines for
he management of patients with valvular heart disease are
ade with Level of Evidence B or C (3), reflecting thebsence of large, prospective randomized clinical trials. peighing risks and benefit.
he current conundrum in IE
rophylaxis recommendations is
ot unique in medicine, but it is
nusual in the field of cardiology.
ata do not exist from large,
ulticenter, prospective, ran-
omized, double-blinded trials.
n this setting, it seems appropri-
te to weigh as best we know the
isks and benefit of therapy and
ry to make an informed (or at least a best-guess) decision.
Are there really risks associated with IE prophylaxis? If
he experience of the individual practitioner is that serious
dverse reactions to antibiotic prophylaxis are extremely
are, the experience of the AHA is that they may be
onexistent (1). If anaphylaxis is not a real risk, neither is
ntibiotic resistance; resistant organisms are not created
ith rare and isolated exposure to an antibiotic. The
nancial cost of 2 g of oral amoxicillin twice yearly is
egligible. Finally, although the medical-legal “cost” of
uideline recommendations is admittedly impossible to
alculate, there is no precedent in medicine to write medical
ractice guidelines with the specific goal of avoiding mal-
ractice claims when guidelines are not followed.
What about benefit? Even if it is only the rare case of IE
hat is successfully prevented with antibiotic prophylaxis,
his is a very real benefit to that patient. On an individual
asis, patients with organic heart valve disease who are
rying to delay or avoid surgical intervention have something
ery real to risk if they develop IE (and a very real benefit if
hey avoid it), even if they are not in the cited groups with
he highest risk of an adverse outcome of IE. If the risk of
rophylaxis is essentially nonexistent, even a very small
otential benefit favors the use of IE prophylaxis in patients
t risk.
n alternative strategy. The AHA and ACC/AHA state-
ents (1,2) do a good job describing the rationale for
hange in IE prophylaxis guideline recommendations. But
hese are only guidelines, and all practitioners in all circum-
tances need not necessarily follow them. The notion of
ndividually weighing risks and benefit is not irrational,
specially in a setting where there are no data that refute a
ime-honored standard of care (and, admittedly, no data to
upport them).
I have personally adopted an approach with my patients
f informed decision-making. For patients with organic
eart valve disease (including both those for whom IE
rophylaxis had been an established norm and those with a
ew diagnosis and so not accustomed to IE prophylaxis), I
iscuss the history of IE prophylaxis, the previous guideline
ecommendations, the new recommendations, the rationale
or change, and the absence of data to either support or
efute their use. Informed patients seem capable of making
ntelligent decisions about their own care. (It is perhaps
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
GI  gastrointestinal
GU  genitourinary
IE  infective endocarditisaternalistic to think, especially in a scenario in which
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IE Prophylaxis May 19, 2009:1852–4ontrolled studies have not been performed, that patients
hould not be involved in a decision about their medical
are.) After discussing the basis of the new recommenda-
ions, and when given a choice, most of my patients remain
omfortable continuing to use antibiotic prophylaxis. If and
hen prospective, randomized trials are performed, rethink-
ng individual decisions will again make sense.
eprint requests and correspondence: Dr. David S. Bach, CVC
oom 2147, SPC 5853, 1500 East Medical Center Drive, Ann
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